Personalized cell therapy takes on Hard-to-Treat cancers
NCT ID NCT07410494
First seen Feb 17, 2026 · Last updated Jun 12, 2026 · Updated 14 times
Summary
This early-stage trial tests a new treatment using donor immune cells (CAR-NK cells) that are specially designed to attack cancer. Up to 85 adults with advanced solid tumors that have not responded to standard therapy will receive cells targeting one or two specific markers found on their tumor. The main goals are to check safety and see if the treatment can shrink or control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
District One Hospital
RECRUITINGBeijing, Beijing Municipality, 086-373, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.